Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Neurochem's Alzhemed (tramiprosate) and Myriad Genetics' Flurizan (R-flurbiprofen) will account for nearly 60% of the market to treat Alzheimer's disease in 2015. Both drugs have shown promise in early clinical development, and will be the first treatments for Alzheimer's disease that modify the course of the disease. Both agents will reach the U.S. market in 2008 and the European market by 2010.

The new Pharmacor report entitled Alzheimer's Disease finds that Alzhemed and Flurizan will account for 46% and 13% of sales, respectively, in the major pharmaceutical markets in 2015. The report also measures the extent to which upcoming patent expiries will reduce the market shares of the current mainstay classes of drugs used to treat Alzheimer's disease-acetylcholinesterase inhibitors (AChEIs) and N-methyl-aspartate (NMDA) receptor antagonists. Drugs in these classes include Eisai/Pfizer's donepezil, Novartis/Sigma-Tau/Esteve's rivastigmine, Merz's Axura, and Lundbeck's Ebixa.

"AChEIs and NMDAs stabilize or modestly delay the cognitive decline that Alzheimer's disease patients experience, but these agents lack true disease-modifying potential," said Kate Hohenberg, director at Decision Resources, Inc. "The need for more effective drugs for Alzheimer's disease is so crucial that any agents that receive regulatory approval will capture market share. Alzhemed and Flurizan will likely show variable efficacy, but they will still capture a significant portion of the market to treat Alzheimer's disease."

About Alzheimer's Disease

Alzheimer's disease is a progressive, neurodegenerative disease characterized by significant loss of function in more than one cognitive domain including memory, reasoning, and judgment. In the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan, prevalent cases numbered more than 5.7 million in 2005.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Drugs From Bayer/Onyx and Pfizer Have Revolutionized the Renal Cell Carcinoma Treatment Market in the United States

View Now